Conatus Pharmaceuticals Inc. (CNAT) News
Filter CNAT News Items
CNAT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest CNAT News From Around the Web
Below are the latest news stories about Conatus Pharmaceuticals Inc that investors may wish to consider to help them evaluate CNAT as an investment opportunity.
Intercept (ICPT) Gains 7.5% YTD on Progress in NASH SpaceIntercept (ICPT) stock gains as it becomes the forerunner in the NASH drug race. |
NASH Scorecard Year to Date: The Winners and the LosersNASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year. |
Conatus Pharmaceuticals Appoints Kathy Scott as Independent Board MemberSAN DIEGO, Nov. 18, 2019 -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) today announced the appointment of Kathleen D. Scott to the Conatus Board of Directors as an additional. |
Conatus Pharmaceuticals (CNAT) Reports Q3 Loss, Misses Revenue EstimatesConatus (CNAT) delivered earnings and revenue surprises of 16.67% and -48.06%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock? |
Conatus Pharmaceuticals Reports Third Quarter 2019 Financial ResultsSAN DIEGO, Nov. 05, 2019 -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the quarter and nine months ended September 30, 2019. Recent. |
Is Conatus Pharmaceuticals Inc.'s (NASDAQ:CNAT) CEO Paid Enough Relative To Peers?In 2005 Steven Mento was appointed CEO of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). First, this article will compare… |
Caspase 3 Market Comprehensive Study by Leading Players- Aptose Biosciences, BeyondSpring Pharmaceuticals, Conatus PharmaceuticalsNov 02, 2019 (HTF Market Intelligence via COMTEX) -- An extensive analysis of the Global Caspase 3 market strategy of the leading companies in the precision… |
Conatus Pharmaceuticals (CNAT) Reports Q2 Loss, Tops Revenue EstimatesConatus (CNAT) delivered earnings and revenue surprises of 83.33% and 54.16%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock? |
The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial ReadoutsBiotech stocks went about in a steady manner this week amid a slew of big pharma and biotech earnings announcements, a handful of FDA approvals and a few clinical trial readouts. Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) was a huge casualty as the micro-cap stock fell steeply on severing of a licensing pact with Sanofi SA (NASDAQ: SNY ). Here are the key catalysts that can sway biotech stocks in the unfolding week. Conferences SVB Leerink Spotlight Series: Rare & Genetic Diseases Conference – Aug. 7, in Boston, Massachusetts Canaccord Genuity Growth Conference - Aug. 7-8, in Boston Clinical Trial Readouts Leap Therapeutics Inc (NASDAQ: LPTX ) is scheduled to provide an update on DKN-01 in combination with Merck & Co., Inc. (NYSE: MRK )'s Keytruda in ornithine transcarbamylase defici... |
Will Conatus Pharmaceuticals (CNAT) Report Negative Q2 Earnings? What You Should KnowConatus (CNAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |